The Food and Drug Administration (FDA) has approved the combination sulopenem etzadroxil and probenecid, an oral antibiotic, to treat bacterial urinary tract infections (UTI) in adult women caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. Manufacturer Iterum Therapeutics anticipates a commercial launch for the drug, branded as Orlynvah, in 2025, according to Reuters. The oral drug is taken twice daily for 5 days and can be used to treat uncomplicated UTIs in women who …
Read More